The relationship between aurothioglucose- and D-penicillamine-induced proteinuria
| Autor: | P. Reekers, L. B. A. Van De Putte, Jan P. Vandenbroucke, F. Speerstra, Johannes J. Rasker |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
medicine.medical_specialty
Immunology Urology urologic and male genital diseases Arthritis Rheumatoid Rheumatology Recurrence Internal medicine medicine Immunology and Allergy Humans Aurothioglucose Proteinuria urogenital system business.industry Incidence (epidemiology) Penicillamine Histocompatibility Antigens Class II General Medicine HLA-DR Antigens medicine.disease female genital diseases and pregnancy complications Increased risk Endocrinology Rheumatoid arthritis Toxicity Gold medicine.symptom business medicine.drug |
| Zdroj: | Scandinavian journal of rheumatology. 13(4) |
| ISSN: | 0300-9742 |
| Popis: | We studied patients with rheumatoid arthritis who have been treated with aurothioglucose (Au) and subsequently with D-penicillamine (DP), and who developed drug-induced proteinuria, over a 10-year period. Twelve patients developed Au-induced and 19 DP-induced proteinuria. Of the 12 patients with Au-induced proteinuria, only 2 (17%) developed DP-induced proteinuria, indicating a slightly increased risk as compared with the overall incidence (9.3 %) of this reaction in 168 DP-treated patients. In addition, only a minority (2 out of 19, 10.6%) of patients with DP-induced proteinuria had previous Au-induced proteinuria. These data may indicate that different mechanisms are operative in Au and DP-induced proteinuria, as is also suggested by the finding that HLA-DR3 was present more frequently in the latter (50%) than in the former (21 %). A history of previous Au-induced proteinuria is insufficient reason to deny these patients the benefits of subsequent treatment with DP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|